Who are NurOwn® (MSC-NTF cells)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, Leukocyte rich platelet rich plasma, Platelet Rich Plasma (PRP), Mesenchymal Stem Cells (MSCs), (H) T-L14, Fibroblasts and keratinocytes.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nurown-msc-ntf-cells.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

NurOwn® (MSC-NTF cells) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NurOwn® (MSC-NTF cells) (NurOwn® (MSC-NTF cells)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cell therapy. Area: Neurology.

phase 3 Cell therapy Neurotrophic factors (NGF, BDNF, GDNF) Neurology Biologic Live · refreshed every 30 min

Target snapshot

NurOwn® (MSC-NTF cells) (NurOwn® (MSC-NTF cells)) — Brainstorm-Cell Therapeutics. NurOwn delivers mesenchymal stem cells engineered to secrete neurotrophic factors that support motor neuron survival and function in amyotrophic lateral sclerosis (ALS).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NurOwn® (MSC-NTF cells) TARGET	NurOwn® (MSC-NTF cells)	Brainstorm-Cell Therapeutics	phase 3	Cell therapy	Neurotrophic factors (NGF, BDNF, GDNF)
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
Leukocyte rich platelet rich plasma	Leukocyte rich platelet rich plasma	University Hospitals Cleveland Medical Center	marketed	Autologous cell therapy / Regenerative medicine product
Platelet Rich Plasma (PRP)	Platelet Rich Plasma (PRP)	Aspetar	marketed	Autologous cell therapy / Regenerative medicine
Mesenchymal Stem Cells (MSCs)	Mesenchymal Stem Cells (MSCs)	The Cleveland Clinic	marketed	Cell therapy
(H) T-L14	(H) T-L14	National Taiwan University Hospital	marketed	T-cell therapy	T-cells
Fibroblasts and keratinocytes	Fibroblasts and keratinocytes	Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus	marketed	Cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cell therapy class)

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · 2 drugs in this class
Bone Therapeutics S.A · 1 drug in this class
DiscGenics, Inc. · 1 drug in this class
Celavie Bioscences, LLC · 1 drug in this class
China Spinal Cord Injury Network · 1 drug in this class
City of Hope Medical Center · 1 drug in this class
Brainstorm-Cell Therapeutics · 1 drug in this class
Dr. Grant M. Pagdin · 1 drug in this class
FDA Office of Orphan Products Development · 1 drug in this class
Biosolution Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NurOwn® (MSC-NTF cells) — Competitive Intelligence Brief. https://druglandscape.com/ci/nurown-msc-ntf-cells. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab